REFERENCES
1. de Bakker JM, van Capelle FJ, Janse MJ, Wilde AA, Coronel R, Becker
AE, Dingemans KP, van Hemel NM, Hauer RN. Reentry as a cause of
ventricular tachycardia in patients with chronic ischemic heart disease:
electrophysiologic and anatomic correlation. Circulation
1988;77:589-606.
2. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N,
Aguinaga L, Leite LR, Al-Khatib SM, Anter E, Berruezo A, Callans DJ,
Chung MK, Cuculich P, d’Avila A, Deal BJ, Della Bella P, Deneke T,
Dickfeld TM, Hadid C, Haqqani HM, Kay GN, Latchamsetty R, Marchlinski F,
Miller JM, Nogami A, Patel AR, Pathak RK, Saenz Morales LC, Santangeli
P, Sapp JL Jr, Sarkozy A, Soejima K, Stevenson WG, Tedrow UB, Tzou WS,
Varma N, Zeppenfeld K. 2019 HRS/EHRA/APHRS/LAHRS expert consensus
statement on catheter ablation of ventricular arrhythmias. Heart Rhythm
2020;17:e2-e154.
3. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe
K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal
Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC)
Investigators. Comparison of beta-blockers, amiodarone plus
beta-blockers, or sotalol for prevention of shocks from implantable
cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA
2006;295:165-171.
4. Briceño DF, Romero J, Villablanca PA, Londoño A, Diaz JC, Maraj I,
Batul SA, Madan N, Patel J, Jagannath A, Mohanty S, Mohanty P, Gianni C,
Della Rocca D, Sabri A, Kim SG, Natale A, Di Biase L. Long-term outcomes
of different ablation strategies for ventricular tachycardia in patients
with structural heart disease: systematic review and meta-analysis.
Europace 2018;20:104-115.
5. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M,
Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME.
Prophylactic catheter ablation for the prevention of defibrillator
therapy. N Engl J Med 2007;357:2657-2665.
6. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E,
Pitschner HF, Kautzner J, Schumacher B, Hansen PS; VTACH study group.
Catheter ablation of stable ventricular tachycardia before defibrillator
implantation in patients with coronary heart disease (VTACH): a
multicentre randomised controlled trial. Lancet 2010;375:31-40.
7. Santangeli P, Frankel DS, Tung R, Vaseghi M, Sauer WH, Tzou WS,
Mathuria N, Nakahara S, Dickfeldt TM, Lakkireddy D, Bunch TJ, Di Biase
L, Natale A, Tholakanahalli V, Tedrow UB, Kumar S, Stevenson WG, Della
Bella P, Shivkumar K, Marchlinski FE, Callans DJ; International VT
Ablation Center Collaborative Group. Early Mortality After Catheter
Ablation of Ventricular Tachycardia in Patients With Structural Heart
Disease. J Am Coll Cardiol 2017;69:2105-2115.
8. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of
defibrillator shocks in patients with heart failure. N Engl J Med
2008;359:1009-1017.
9. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R,
Fain E, Gent M, Connolly SJ; DINAMIT Investigators. Prophylactic use of
an implantable cardioverter-defibrillator after acute myocardial
infarction. N Engl J Med 2004;351:2481-2488.
10. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF,
Thibault B, Rivard L, Gula L, Leong-Sit P, Essebag V, Nery PB, Tung SK,
Raymond JM, Sterns LD, Veenhuyzen GD, Healey JS, Redfearn D, Roux JF,
Tang AS. Ventricular Tachycardia Ablation versus Escalation of
Antiarrhythmic Drugs. N Engl J Med 2016;375:111-121.
11. Haqqani HM, Kalman JM, Roberts-Thomson KC, Balasubramaniam RN, Rosso
R, Snowdon RL, Sparks PB, Vohra JK, Morton JB. Fundamental differences
in electrophysiologic and electroanatomic substrate between ischemic
cardiomyopathy patients with and without clinical ventricular
tachycardia. J Am Coll Cardiol 2009;54:166-173.
12. Romero J, Di Biase L, Diaz JC, Quispe R, Du X, Briceno D, Avendano
R, Tedrow U, John RM, Michaud GF, Natale A, Stevenson WG, Kumar S. Early
Versus Late Referral for Catheter Ablation of Ventricular Tachycardia in
Patients With Structural Heart Disease: A Systematic Review and
Meta-Analysis of Clinical Outcomes. JACC Clin Electrophysiol
2018;4:374-382.
13. Tung R, Vaseghi M, Frankel DS, Vergara P, Di Biase L, Nagashima K,
Yu R, Vangala S, Tseng CH, Choi EK, Khurshid S, Patel M, Mathuria N,
Nakahara S, Tzou WS, Sauer WH, Vakil K, Tedrow U, Burkhardt JD,
Tholakanahalli VN, Saliaris A, Dickfeld T, Weiss JP, Bunch TJ, Reddy M,
Kanmanthareddy A, Callans DJ, Lakkireddy D, Natale A, Marchlinski F,
Stevenson WG, Della Bella P, Shivkumar K. Freedom from recurrent
ventricular tachycardia after catheter ablation is associated with
improved survival in patients with structural heart disease: An
International VT Ablation Center Collaborative Group study. Heart Rhythm
2015;12:1997-2007.
14. Kuck KH, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS, Zarse
M, Hohnloser SH, Kautzner J, Willems S; SMS Investigators. Impact of
Substrate Modification by Catheter Ablation on Implantable
Cardioverter-Defibrillator Interventions in Patients With Unstable
Ventricular Arrhythmias and Coronary Artery Disease: Results From the
Multicenter Randomized Controlled SMS (Substrate Modification Study).
Circ Arrhythm Electrophysiol 2017;10:e004422. doi:
10.1161/CIRCEP.116.004422.
15. Willems S, Tilz RR, Steven D, Kääb S, Wegscheider K, Gellér L, Meyer
C, Heeger CH, Metzner A, Sinner MF, Schlüter M, Nordbeck P, Eckardt L,
Bogossian H, Sultan A, Wenzel B, Kuck KH; BERLIN VT Investigators.
Preventive or Deferred Ablation of Ventricular Tachycardia in Patients
with Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT):
A Multicenter Randomized Trial. Circulation 2020;141:1057-1067.
16. Dinov B, Fiedler L, Schönbauer R, Bollmann A, Rolf S, Piorkowski C,
Hindricks G, Arya A. Outcomes in catheter ablation of ventricular
tachycardia in dilated nonischemic cardiomyopathy compared with ischemic
cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT
(HELP-VT) Study. Circulation 2014;129:728-736.
17. Tschabrunn CM, Roujol S, Nezafat R, Faulkner-Jones B, Buxton AE,
Josephson ME, Anter E. A swine model of infarct-related reentrant
ventricular tachycardia: Electroanatomic, magnetic resonance, and
histopathological characterization. Heart Rhythm 2016;13:262-273.
18. Arenal A, Pérez-David E, Avila P, Fernández-Portales J, Crisóstomo
V, Báez C, Jiménez-Candil J, Rubio-Guivernau JL, Ledesma-Carbayo MJ,
Loughlin G, Bermejo J, Sánchez-Margallo FM, Fernández-Avilés F.
Noninvasive identification of epicardial ventricular tachycardia
substrate by magnetic resonance-based signal intensity mapping. Heart
Rhythm 2014;11:1456-1464.
19. Romero J, Cerrud-Rodriguez RC, Di Biase L, Diaz JC, Alviz I,
Grupposo V, Cerna L, Avendano R, Tedrow U, Natale A, Tung R, Kumar S.
Combined Endocardial-Epicardial Versus Endocardial Catheter Ablation
Alone for Ventricular Tachycardia in Structural Heart Disease: A
Systematic Review and Meta-Analysis. JACC Clin Electrophysiol
2019;5:13-24.
20. Winterfield JR, Kent AR, Karst E, Dalal N, Mahapatra S, Bunch TJ,
Reynolds MR, Wilber DJ. Impact of ventricular tachycardia ablation on
health care utilization. Heart Rhythm 2018;15:355-362.